Tech Company Financing Transactions
Actimed Therapeutics Funding Round
On 1/5/2023, Actimed Therapeutics raised $6.1 million in Seed funding from Mankind Pharma.
Transaction Overview
Company Name
Announced On
1/5/2023
Transaction Type
Venture Equity
Amount
$6,070,000
Round
Seed
Investors
Mankind Pharma (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the development of its portfolio, including preparation for the Phase 2b/3 programme for its lead asset, S-pindolol benzoate, being developed for the treatment of cancer cachexia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
The Old Bakehouse, Course Road, Ascot
Berkshire, SL5 7HL
UK
Berkshire, SL5 7HL
UK
Phone
Undisclosed
Website
Email Address
Overview
We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no globally approved pharmaceutical product for the treatment or prevention of cancer-related cachexia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robin Bhattacherjee
Chief Medical Officer
Frank Misselwitz
Browse more venture capital transactions:
Prev: 1/5/2023: Forj venture capital transaction
Next: 1/5/2023: Opsys Tech venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs